TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9779135
Drug: Hypertonic saline
Normalized name: ENTSOL Hypertonic Saline Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypertonic saline (100 ml 10% NaCl)
Study: 8286206
Drug: IL-2 plus
Normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IL-2 plus MLT (40 mg day-1 orally at 8.00 p.m. every day starting 7 days before IL-2)
Study: 3051530
Drug: Aspirin (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (50 mg/day, adjusted up to 100 mg/day)
Study: 26139202
Drug: MTX +
Normalized name: MTX
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MTX + T-614 (50 mg/day for 24 weeks)
Study: 26139202
Drug: MTX (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX (10 mg/week for first 4 weeks, then 12.5 mg/week for 20 weeks)
Study: 17382417
Drug: Low serum
Normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low serum digoxin concentrations (0.5-0.9 ng/ml)
Study: 14520775
Drug: 18% carbamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18% carbamide peroxide gel (Colgate Simply White) applied twice daily
Study: 9365358
Drug: Subacromial local
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subacromial local anesthetic injection
Study: 27871575
Drug: Alfentanil 55
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil 55 μg/kg
Study: 27871575
Drug: Alfentanil doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil doses (0, 10, 20, 30, 40, 50, and 60 μg/kg)
Study: 27871575
Drug: Alfentanil (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (various doses)
Study: 22775448
Drug: Weekly Swedish
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly Swedish massage
Study: 22775448
Drug: Twice-weekly Swedish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly Swedish massage
Study: 18201457
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TA) 100 mg
Study: 18201457
Drug: Topical tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical tranexamic acid (TA) 1 g
Study: 18201457
Drug: Combined results
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined results from TA groups (100 mg and 1 g)
Study: 18201457
Drug: Topical epsilon‐aminocaproic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical epsilon‐aminocaproic acid (EACA)
Study: 9816716
Drug: Mivacurium (non-priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (non-priming group, n = 20) - 0.25 mg/kg as a single intubating dose
Study: 9816716
Drug: Mivacurium (priming
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mivacurium (priming group, n = 20) - 0.225 mg/kg preceded by 0.025 mg/kg 3 min earlier
Study: 9816716
Drug: Succinylcholine (control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Succinylcholine (control group, n = 20) - 1 mg/kg as an intubating bolus
Study: 2700113
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day mepindolol (Group A)
Study: 2700113
Drug: 200 mg/day
Normalized name: alpelisib 200 mg/day (200 mg x 1) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/day metoprolol duriles (Group B)
Study: 2700113
Drug: Both beta-blockers
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both beta-blockers (mepindolol and metoprolol)
Study: 29460812
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (∼400 mg flavonoids, equivalent to 2-3 cups of tea)
Study: 27241836
Drug: Acute aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute aspirin supplementation
Study: 27241836
Drug: Chronic aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic aspirin supplementation
Study: 21405957
Drug: Allopurinol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (150 mg daily for 8 weeks) with ACE-I (perindopril)
Study: 21405957
Drug: Allopurinol (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (150 mg daily for 8 weeks) with thiazide (hydrochlorothiazide)
Study: 18626522
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg premedication
Study: 14610410
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg bicalutamide
Study: 11212479
Drug: Fusidic acid
Normalized name: Fusidic acid
DrugBank: Fusidic acid (DB02703)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fusidic acid cream applied in nostrils, 20 mg/gm, twice a day for four weeks
Study: 9104518
Drug: Group 1A
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1A (portal injections with lidocaine, intraarticular lidocaine, placebo femoral nerve block)
Study: 9104518
Drug: Group FNB
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group FNB (femoral 3-in-1 nerve block with chloroprocaine, placebo portal injections, placebo intraarticular saline)
Study: 9104518
Drug: Group FNB
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group FNB + IA (femoral 3-in-1 nerve block, intraarticular lidocaine, placebo portal injections)
Study: 3549871
Drug: CNS stimulants
Normalized name: CNS STIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNS stimulants (methylphenidate)
Study: 30002346
Drug: Whole-body cryotherapy
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryotherapy (WBC) treatment after exercise (-140 °C, 3 min)
Study: 30002346
Drug: Whole-body cryotherapy
Normalized name: Insects (whole body), mite dermatophagoides farinae
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole-body cryotherapy (WBC) treatment after exercise
Study: 26400901
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection (SI)
Study: 22265921
Drug: NT‐proBNP >1800
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP >1800 pg/mL
Study: 22265921
Drug: NT‐proBNP <150
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT‐proBNP <150 pg/mL
Study: 19720489
Drug: Single-dose gadobutrol
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose gadobutrol (0.1 mmol/kg b.w.)
Study: 19720489
Drug: Double-dose gadobutrol
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Double-dose gadobutrol
Study: 19720489
Drug: Single-dose gadobenate-dimeglumine
Normalized name: Gadobenate Dimeglumine
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose gadobenate-dimeglumine
Study: 16568409
Drug: Weight training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight training (twice-weekly)
Study: 12666710
Drug: 0.12% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.12% chlorhexidine mouthrinse (15 ml, 30 seconds)
Study: 12666710
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine mouthrinse (10 ml, 60 seconds)
Study: 9194621
Drug: Maternal intravenous
Normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal intravenous magnesium sulfate therapy
Study: 1535083
Drug: BAY u
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAY u 3405 (20 mg orally 1 hour before challenges)
Study: 3032562
Drug: enalapril 10
Normalized name: enalapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 10 mg orally
Study: 3032562
Drug: enalapril 5
Normalized name: enalapril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 5 mg intravenously
Study: 3032562
Drug: enalapril (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril (oral and intravenous) and enalaprilat (intravenous)
Study: 23213082
Drug: Restorative occupational
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restorative occupational therapy intervention
Study: 11158452
Drug: Early dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Early dexamethasone treatment
Study: 11158452
Drug: Delayed selective
Normalized name: omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delayed selective treatment
Study: 3298406
Drug: Lymphoblastoid interferon
Normalized name: interferon alfa-n1 lymphoblastoid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphoblastoid interferon (thrice weekly for 6 months after a 5-day induction phase)
Study: 20556258
Drug: Platform-switched implants
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platform-switched implants (n = 75)
Study: 20556258
Drug: Nonplatform-switched implants
Normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonplatform-switched implants (n = 14)
Study: 12020739
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba (360 mg)
Study: 12020739
Drug: Ginseng (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginseng (400 mg)
Study: 12020739
Drug: Ginkgo/ginseng combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo/ginseng combination (960 mg)
Study: 30624753
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder (MNP) with 0 mg Zn/sachet
Study: 30624753
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder (MNP) with 5 mg Zn/sachet
Study: 30624753
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder (MNP) with 10 mg Zn/sachet
Study: 30624753
Drug: Micronutrient powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronutrient powder (MNP) with 15 mg Zn/sachet
Study: 30624753
Drug: Comparison with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison with published data on child zinc absorption
Study: 24503952
Drug: Etravirine (ETR)
Normalized name: Etravirine
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Etravirine (ETR) 400 mg/day
Study: 24503952
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued protease inhibitor regimen)
Study: 22824079
Drug: S-1 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: S-1 40 mg/m2 bid for 21 days plus cisplatin 60 mg/m2 (day 8) every 5-week cycle
Study: 22824079
Drug: Capecitabine 1000
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine 1000 mg/m2 bid for 14 days plus cisplatin 80 mg/m2 (day 1) every 3-week cycle
Study: 19157559
Drug: 0.5% timolol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% timolol gel forming solution once every morning
Study: 17998079
Drug: Mixed-mode survey
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed-mode survey design (phone administration followed by mail follow-up for nonresponders)
Study: 14729431
Drug: Seropositive for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seropositive for IgG antibodies at baseline
Study: 14729431
Drug: Seropositive for
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seropositive for IgA antibodies at baseline
Study: 14729431
Drug: Increasing anti-Chlamydia
Normalized name: Chlamydia trachomatis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing anti-Chlamydia pneumoniae antibody titers
Study: 12078851
Drug: Benzoyl peroxide
Normalized name: Benzoyl Peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Benzoyl peroxide 5%/clindamycin phosphate 1% gel
Study: 2952685
Drug: Clindamycin phosphate
Normalized name: Clindamycin Phosphate
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clindamycin phosphate 1% solution
Study: 368965
Drug: Polyethylene glycol
Normalized name: Polyethylene Glycol
DrugBank: Polyethylene glycol (DB09287)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polyethylene glycol ointment
Study: 368965
Drug: Ointment with
Normalized name: OINTMENT WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment with 60% DMSO
Study: 368965
Drug: Ointment with
Normalized name: OINTMENT WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment with 5% IDU and 60% DMSO
Study: 368965
Drug: Ointment with
Normalized name: OINTMENT WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment with 40% IDU and 60% DMSO
Study: 25824556
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium sulfate (MgSO4) 5 g in normal saline infused over 6 hours, administered 2 days before surgery, repeated the day before and during surgery.
Study: 17298712
Drug: High monounsaturated
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High monounsaturated fat diet (HMF; 50% fat, 20% protein (67 g/d), 30% carbohydrate)
Study: 17298712
Drug: High protein
Normalized name: Vital High Protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: High protein diet (HP; 40% protein (136 g/d), 30% fat, 30% carbohydrate)
Study: 15105231
Drug: Morphine 100
Normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 100 microg plus clonidine 60-150 microg (MC60-150)
Study: 15105231
Drug: Morphine 100
Normalized name: MORPHINE 100MG/NALTREXONE 4MG SA CAP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine 100 microg plus clonidine 30 microg
Study: 9892859
Drug: Fluoxetine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (20 mg, mane)
Study: 9892859
Drug: Dothiepin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dothiepin (75 mg rising to 150 mg in the second week, nocte)
Study: 1723772
Drug: Ro 40-5967
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 40-5967 (200 mg)
Study: 1723772
Drug: Ro 40-5967
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 40-5967 (100 mg)
Study: 1723772
Drug: Ro 40-5967
Normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ro 40-5967 (all doses)
Study: 21273900
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of triamcinolone acetonide
Study: 21273900
Drug: 4 ml
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 ml of 1% procaine HCl
Study: 21273900
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg of triamcinolone acetonide and 4 ml of 1% procaine HCl
Study: 15505867
Drug: Intracoronary radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary radiation therapy with rhenium-188-DTPA-filled balloon
Study: 9510277
Drug: Polytetrafluoroethylene Patch
Normalized name: polytetrafluoroethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polytetrafluoroethylene Patch Closure (PTFE-P)
Study: 23514767
Drug: Higher iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher iron supplement
Study: 20142600
Drug: Pre-emptive treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive treatment (skin moisturizers, sunscreen, topical steroid, doxycycline)
Study: 20142600
Drug: Reactive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reactive treatment (after skin toxicity developed)
Study: 24948702
Drug: Pre-emptive treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-emptive treatment
Study: 11344197
Drug: human corticotropin-releasing
Normalized name: Human corticotropin-releasing factor
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: human corticotropin-releasing hormone (hCRH)
Study: 3548982
Drug: Diflunisal (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (500 mg BID, increased to 750 mg BID for non-responders)
Study: 3548982
Drug: Naproxen (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (375 mg BID, increased to 500 mg BID for non-responders)
Study: 29907624
Drug: Rectal douching/enema
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal douching/enema (RD) performed weekly or more
Study: 24356253
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) administered twice daily according to FDA weight bands
Study: 24356253
Drug: Lopinavir/ritonavir (LPV/r)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir (LPV/r) pediatric tablets (100/25 mg) administered once daily according to FDA weight bands
Study: 18042975
Drug: Bronchodilator groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bronchodilator groups (salbutamol and ipratropium)
Study: 15653705
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 30 mg kg(‐1) as a bolus before induction and 10 mg kg(‐1) h(‐1) by infusion
Study: 15653705
Drug: Clonidine 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine 3 microg kg(‐1) as a bolus before induction and 2 microg kg(‐1) h(‐1) by infusion
Study: 10434229
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg chewable tablet of montelukast
Study: 10434229
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg film-coated tablet of montelukast (adults)
Study: 7788204
Drug: Fenoterol inhaled
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fenoterol inhaled 10 min before induction
Study: 7788204
Drug: Placebo inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaled 10 min before induction
Study: 2112150
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist (GnRH‐a) leuprolide acetate depot
Study: 28185643
Drug: Oral triiodothyronine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral triiodothyronine (T3; 1 μg/kg per body weight/dose) administered every 6 hours for 60 hours after induction of anesthesia
Study: 22775479
Drug: Topical Xilei
Normalized name: Xilep
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical Xilei San (0.1 g/dose per day)
Study: 22775479
Drug: Topical Xilei
Normalized name: Xilep
DrugBank: Rufinamide (DB06201)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical Xilei San
Study: 11953077
Drug: Nitroglycerin patch
Normalized name: Nitroglycerin Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin patch
Study: 2132303
Drug: Polyoestradiol phosphate
Normalized name: POLYESTRADIOL
DrugBank: Polyestradiol phosphate (DB09369)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Polyoestradiol phosphate (PEP) 160 mg/month i.m.
Study: 31915308
Drug: Mirtazapine (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (dose not specified) over 28 days
Study: 25424132
Drug: Supervised implementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised implementation of an oral healthcare protocol and education
Study: 23978872
Drug: 450 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 450 mg/day UDCA
Study: 16163627
Drug: Famciclovir 125
Normalized name: famciclovir 125 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 125 mg twice daily for 5 days
Study: 16163627
Drug: Famciclovir 250
Normalized name: famciclovir 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 250 mg twice daily for 5 days
Study: 16163627
Drug: Famciclovir 500
Normalized name: famciclovir 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Famciclovir 500 mg twice daily for 5 days
Study: 12188088
Drug: Intact bovine
Normalized name: Pegademase Bovine
DrugBank: Pegademase (DB00061)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intact bovine colostrum protein powder (60 g x day(‐1))
Study: 8979563
Drug: All three
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: All three drugs (PB, PHT, SVP)
Study: 6150121
Drug: Activated charcoal,
Normalized name: activated charcoal, sterile
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal, 50 g, given 5 min after 400 mg cimetidine + 10 mg pindolol
Study: 29462506
Drug: LCPT (extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCPT (extended-release tacrolimus tablets)
Study: 27244765
Drug: Triptorelin 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 0.1 mg (Group A)
Study: 27244765
Drug: Triptorelin 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 50 µg (Group B)
Study: 27244765
Drug: Triptorelin 25
Normalized name: triptorelin 11.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triptorelin 25 µg (Group C)
Study: 25755182
Drug: Abdominal subcutaneous
Normalized name: PAD,ABDOMINAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abdominal subcutaneous fat (per SD increment) in women
Study: 20337206
Drug: Letrozole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (5 mg daily from day 3-7 of menstrual cycle)
Study: 20337206
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (100 mg daily from day 3-7 of menstrual cycle)
Study: 20337206
Drug: Letrozole (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (5 mg daily)
Study: 3051880
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (100 mg daily)
Study: 11792152
Drug: Ibuprofen (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (600 mg/day)
Study: 7730962
Drug: Customary oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Customary oral hygiene care
Study: 28889155
Drug: Ultrasound (US)‐guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound (US)‐guided transversus abdominis plane (TAP) block, 0.3 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Study: 28889155
Drug: Ilio‐inguinal/ilio‐hypogastric (II/IH)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ilio‐inguinal/ilio‐hypogastric (II/IH) block, 0.7 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin
Study: 28889155
Drug: Caudal block,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caudal block, 0.5 ml/kg of 0.25% levobupivacaine with 1/200,000 adrenalin